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Characterization of the 5¢ untranslated region of a and b isoforms
of the human thromboxane A2 receptor (TP)
Differential promoter utilization by the TP isoforms
Adrian T. Coyle*, Sinead M. Miggin* and B. Therese Kinsella
Department of Biochemistry, University College Dublin, Ireland
In humans, thromboxane (TX) A2 signals through two
TXA2 receptor (TP) isoforms, TPa and TPb, that diverge
within their carboxyl terminal cytoplasmic (C) tail regions
and arise by differential splicing. The human TP gene con-
tains three exons E1–E3; while E1 exclusively encodes
5¢ untranslated region (UTR) sequence, E2 andE3 represent
the main coding exons. An additional noncoding exon, E1b
was identified within intron 1. Additionally, the TP gene
contains two promoters P1 and P2 located 5¢ of E1 and E1b,
respectively.
Herein, we investigated the molecular basis of the differ-
ential expression of the TP isoforms by characterizing the
5¢ UTRof the TP transcripts.While E1 andE1bwere found
associated with TP transcript(s), their expression was
mutually exclusive. 5¢ rapid amplification of cDNA ends
(5¢ RACE) established that the major transcription
initiation (TI) sites were clustered between )115 and )92
within E1 and at )99 within E1b. While E1 and E1b
sequences were identified on TPa transcript(s), neither exis-
ted on TPb transcript(s). More specifically, TPa and TPb
transcripts divergedwithinE2and themajorTI sites forTPb
transcripts mapped to )12/)15 therein. Through genetic
reporter assays, a previously unrecognizedpromoter, termed
P3, was identified on the TP gene located immediately 5¢ of
)12. The proximity of P3 to theTI site ofTPb suggests a role
for P3 in the control of TPb expression and implies that TPa
and TPb, in addition to being products of differential spli-
cing, are under the transcriptional control of distinct pro-
moters.
Keywords: thromboxane receptor; isoforms; splicing; pro-
moter; 5¢ untranslated region.
Thromboxane (TX) A2, generated through the sequential
metabolism of arachidonic acid by cyclooxygenases 1/2
and TXA2 synthase, acts as a potent agonist of platelet
activation and aggregation and mediates a diversity of
actions in a number of other target cell or tissue types [1].
TXA2 signals through interaction with its specific cell
surface TXA2 receptor, also termed TP, a member of the
G-protein coupled receptor (GPCR) superfamily [2,3]. In
humans, but not in other species thus far investigated, the
TP exists as two isoforms, referred to as TPa and TPb
[2,3] that are encoded by a single TP gene located on
chromosome 19p13.3 and arise by a novel differential
splicing mechanism [3,4]. TPa and TPb are identical for
their N-terminal 328 amino acid residues but differ
exclusively in their carboxyl terminal cytoplasmic (C) tail
sequences [2,3] such that TPa (343 amino acids) and TPb
(407 amino acids) have some 15 and 79 amino acids
within their divergent C-tail sequences, respectively. In
humans, the single TP gene is composed of three major
exons, E1–E3, and two intervening introns I1 and I2 [4].
Through primer extension analysis, an additional exon,
referred to as E1b, was also identified within I1 [4]. Two
individual promoters (P), designated P1 and P2, each
with distinct signature transcription factor binding sites,
located 5¢ of E1 and E1b sequences, respectively, were
identified [4] and a number of independent studies have
indicated that P1 may be the major promoter [5–7].
While E1 and E1b each exclusively encode 5¢ untrans-
lated region (UTR) sequences, E2 encodes some 83
nucleotides of 5¢ UTR and, along with E3, represents the
major coding exons of both TPa and TPb receptors [4].
The coding sequence of TPa and TPb mRNAs are
identical from nucleotide +1 to +983 nucleotides (where
the initiation codon is designated +1), but diverge within
E3 whereby excision of nucleotides +984 to +1642,
representing intron 3b sequences, creates a mRNA
transcript with a new open reading frame encoding TPb
divergent sequences [3,4]. Retention of these potential
intron 3b sequences within E3 of the TPa mRNA
encodes TPa divergent sequences [3].
While the biologic relevance for the existence of two TP
receptors in humans is currently unknown, there is
substantial evidence that they mediate differential signalling
[8–11] and are subject to differential regulation [12–16],
providing compelling evidence that the individual TP
isoforms have distinct physiologic/pathophysiologic roles.
Consistent with this view, it appears that the TPa and TPb
are also subject to differential expression [17,18]. In a study
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investigating the expression of the mRNAs encoding the
TPs throughout a range of cell and tissues of particular
relevance to TXA2 biology, most cell/tissue types examined
were found to express mRNAs for both the TPa and TPb
isoforms [17]. While TPa mRNA expression was constant
and predominated, levels of TPb mRNA expression varied
enormously and, hence, extensive differences in the relative
ratios of TPa : TPb mRNA expression were identified [17].
Additionally, whilst isoform specific antibodies permitted
the detection of TPa, but not TPb, expression in human
platelets [18], both receptors were detected in cultured
vascular smooth muscle cells [19]. The molecular basis of
this differential TP expression is currently unknown but
suggests that the TP receptors may not only be the products
of differential splicing but may also be subject to differential
transcriptional regulation. Moreover, the identification of
two putative promoters (P), P1 and P2, on the single TP
gene raises the possibility that the TPa and TPb isoforms
may be under the transcriptional control of distinct
promoters [4].
In the current study, we sought to investigate the
molecular basis of the differential expression of TPa and
TPb isoforms. Our initial aim was to map the patterns of
exon usage in the 5¢ UTR of the major TP transcripts
expressed in megakaryocytic human erythroleukemic
(HEL) 92.1.7 cells and in trophoblast TM-1 cells [17]
and, through the 5¢ rapid amplification of cDNA ends
(5¢ RACE), to identify the major transcription initiation
(TI) site(s) within the TP gene in both cell types.
Moreover, we also sought to identify the patterns of exon
usage within the 5¢ UTR(s) of the individual TPa and
TPb mRNA transcripts and to map their major TI site(s),
in both HEL cells and TM-1 cells. Whilst sequences
corresponding to E1 and E1b sequences were found to
exist within the TPa mRNA transcripts, neither E1 nor
E1b sequences were found associated with TPb mRNAs
and, more specifically, TPa and TPb mRNA sequences
were found to diverge at nucleotide )12 within E2,
representing the site of transcription initiation for TPb
mRNA sequences. Moreover, through genetic reporter
assays, a previously unidentified promoter, herein desig-
nated P3, located 5¢ of the )12 region on the human TP
gene has been uncovered. The location of P3 close to the
transcription initiation site of TPb suggests a role for this
promoter in the control of TPb expression and indeed
implies that the TPa and TPb are under the transcrip-
tional control of distinct promoters.
E X P E R I M E N T A L P R O C E D U R E S
Materials
UltraspecTM total RNA isolation system was obtained
from Biotecx Laboratories, Houston, TX, USA. Perfectly
Blunt Cloning kit, and Pellet-paint coprecipitant, was
obtained from Calbiochem-Novabiochem, Nottingham,
UK. Random hexamers, 5¢ RACE system and eLONGase
enzyme mix were purchased from Life Technologies Inc.,
Gaithersburg, MD, USA. Mouse moloney leukemia virus
(MMLV) reverse transcriptase (RT), recombinant
RNasin ribonuclease inhibitor, pGEM DNA molecular
weight markers, DNA polymerase I Large (Klenow)
fragment, deoxynucleotide triphosphates, restriction endo-
nucleases, RQ DNase I, pGL3 Basic, pGL3 Enhancer and
pRL Thymidine Kinase reporter vectors and Dual Lucif-
erase Reporter Assay System were obtained from
Promega Corporation, Madison, WI, USA. Taq DNA
polymerase, T4 DNA ligase and calf intestinal alkaline
phosphatase were obtained from Roche Molecular Bio-
chemicals, Sussex, UK. Nytran supercharge membrane
(0.45 lm) was from Schleicher and Schuell. T7 Sequenase
Version 2.0 DNA sequencing kit was obtained from US
Biochemical Corp. Oligonucleotides were synthesized by
Genosys Biotechnologies, Cambridgeshire, UK. RNeasy
Mini Kit and Effectene Transfection Reagent was pur-
chased from Qiagen Ltd, Crawley, West Sussex, UK.
DMRIE-C Reagent was purchased from Life Technolo-
gies. All other reagents were of molecular biology grade.
Cell culture
All mammalian cells were grown at 37 C in a humid
environment with 5% CO2. Human erythroleukemic
(HEL) 92.1.7 cells [20] and human embryonic kidney
(HEK) 293 cells were cultured in RPMI 1640, 10% fetal
bovine serum and in Eagle’s minimal essential medium,
10% fetal bovine serum, respectively. The primary tropho-
blast cell line TM-1 [17] was grown in Dulbecco’s minimal
essential medium, 10% fetal bovine serum.
RT-PCR
Total RNA was isolated using the Ultraspec RNA
isolation procedure and aliquots (25 lg) were treated with
6.25 U RQ DNase I in the presence of 40 U RNasin
ribonuclease inhibitor using standard methodology [21].
DNase I treated total RNA (1.4 lg) was converted to
first strand cDNA with mouse moloney leukemia virus
(MMLV) RT in the presence of random hexamers
(100 lM), essentially as previously described [17].
Thereafter, aliquots (3.5 lL) of first strand cDNA were
used as templates in each PCR reaction (25 lL) in the
presence of 10 mM Tris/HCl, pH 8.3, 50 mM KCl, 2 mM
MgCl2, 0.2 mM dNTPs, 6.7% glycerol, 1 lM sense primer,
1 lM antisense primer, 1 U Taq DNA polymerase.
The oligonucleotide primers used include Kin2:
5¢-dCAGCCGTCTCTCCTCCAGGGT-3¢ (+72 to +52,
Exon 2); Kin3: 5¢-dTGTGGGCCGGAAACAGGGC-3¢
(+45 to +27, Exon 2); Kin6: 5¢-dGTGGCCCAACGG
CAGTTC-3¢ (+3 to +20, Exon 2); Kin16: 5¢-dGAGAT
GATGGCTCAGCTCCT-3¢ (+724 to +743, Exon 2);
Kin45: 5¢-dCCTGATGGGGTGGTGAC-3¢ ()40 to )24,
Exon 2); Kin46: 5¢-dGGCTCCGGAGCCATGTG-3¢ ()12
to +5, Exon 2); Kin47: 5¢-dTGACTGATCCCTCAGGG
-3¢ ()27 to )11, Exon 2); Kin60: 5¢-dCGAGGCCGCAG
AGGAAGGTGA-3¢ (+211 to +191, Exon 2); Kin129:
5¢-dCCCTCGCCCCACCCTCGG-3¢ ()196 to )180, Exon
1); Kin130: 5¢-dGTTCAGTGGCACGATCTT-3¢ ()198 to
)181, Exon 1b); Gf: 5¢-dTGAAGGTCGGAGTCAACG
-3¢ (+71 to +89, glyceraldehyde-3-phosphate dehydrogen-
ase GAPDH mRNA) and Gr: 5¢-dCATGTGGGC
CATGAGGTC-3¢ (+1053–1035, GAPDHmRNA), where
corresponding nucleotide positions within the TPmRNAor
GAPDHmRNA sequences are indicated in parentheses. In
order to specifically amplify TPa mRNA sequences, the
primer Kin75, with the sequence 5¢-dCCAGCCCCT
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GAATCCTCA 3¢ complementary to nucleotides +1121 to
+1106 found on TPa, but not TPb mRNA sequences, was
used as antisense primer throughout. Similarly, in order to
specifically amplify TPb mRNA transcripts, the primer
Kin21, with the sequence 5¢-dAGACTCCGTCTGG
GCCG-3¢ complementary to nucleotides +992 to +976,
and traversing a splice site at +983/1693 within the TPa
mRNA, was used as antisense primer throughout.
To ascertain their identities, Kin130/2 and the Kin129/2
RT-PCR amplification products, were subcloned into
pBluescript II SK(–) using standard methodology [21] and
then subjected to DNA sequence analysis. Where indicated,
densitometic analysis of RT-PCR products were performed
essentially as previously described [17].
5¢ Rapid amplification of cDNA ends (5¢ RACE)
The 5¢RACE System, Version 2TM (Life Technologies, Inc.)
was used essentially as described by supplier. Three
independent 5¢ RACE experiments were carried out and
are designated (i) (ii) or (iii). Briefly, total RNA was
converted to first strand cDNA using Superscript reverse
transcriptase and, for 5¢ RACE experiment (i), using the
TP-specific antisense primer Kin60 (+ 211 to +191, Exon
2); for 5¢ RACE experiment (ii), using the TP-specific
antisense primer Kin58: 5¢-dCAGAGTGAGACTCCG
TCTG-3¢(+999 to +981, TPb specific primer; Exon 2);
and for 5¢ RACE experiment (iii) using the TP-specific
antisense primer Kin51: 5¢-dGGGACAGGCCGAAGAA
GATCATGAC-3¢ (+355 to +331, Exon 2). Thereafter,
following dC-tailing by terminal deoxynucleotidyl transfer-
ase, first strand cDNA was used as templates in the first
round of PCR amplifications using the sense anchor primer,
AAP (5¢-dGGCCACGCGTCGACTAGTACGGGIIGG
GIIGGGIIG-3¢) and for 5¢ RACE experiments (i) (ii) and
(iii), using the TP-specific antisense primers Kin2, Kin21
and Kin60, respectively. Thereafter, second round or nested
PCR amplifications were performed with the sense abridged
universal anchor primer, AUAP (5¢-dGGCCACGCGTC
GACTAGTAC-3¢) and for 5¢ RACE experiments (i) (ii)
and (iii), using the TP-specific primers Kin3, Kin60 and
Kin2, respectively.
The nested 5¢ RACE amplification products were
cloned into pSTBlue-1, using the Perfectly Blunt Cloning
kit, as described by the manufacturer (Novagen). In the
case of the TPb-specific 5¢ RACE amplifications (i.e
5¢ RACE experiment (ii) using Kin58 during the first
strand cDNA synthesis), AUAP/Kin60 products were
blunt end subcloned into pBluescript II SK(–). All
resulting recombinant plasmids were subject to DNA
sequence analysis.
Southern blot analysis
Southern blot analysis of the RT-PCR and 5¢ RACE
amplification products was carried out using standard
methodology [21]. Oligonucleotide primers Kin2, Kin46,
Kin47 or Kin119 (5¢-dCAGAAGACTGTGGATGGC-3¢,
corresponding to nucleotides +552 to +570 of GAPDH
mRNA) were each 5¢ end labelled with T4 polynucleotide
kinase and were used as hybridization probes as previously
described [17]. Radioactive images were captured by
autoradiography on Fuji New RX Film.
Construction of luciferase-based genetic reporter
plasmids
To investigate the relative strengths of the putative
promoters located within the TP gene, gene fragments
encoding the two previously identified promoters Promoter
1 and 2 [4] and a third novel promoter, herein designated
Promoter 3, were subcloned into two genetic reporter
plasmids pGL3Basic and pGL3Enhancer, containing a
SV40 enhancer located downstream of the luciferase gene
(Promega). Gene fragments encoding each promoter were
amplified by PCR using as template a recombinant cosmid
pWE15: TXR containing the entire human TP gene [22].
Promoter 1 fragment was amplified with the sense primer
Kin108 (5¢-dGAGAGGTACCGAGGGCGCGTGAGCT
GGGGAG-3¢, corresponding to nucleotides )8500 to
)8479, where the )designation indicates nucleotides 5¢
relative to the translational initiation codon ATG, which
is designated +1) and the antisense primer Kin109
(5¢-dAGAGACGCGTCTTCAGAGACCTCATCTGCG
GGG-3¢, corresponding to nucleotides )5922 to )5895).
Promoter 2 fragment was amplified using the sense primer
Kin110 (5¢-dGAGAGGTACCGTGCTGCTCTACTGC
CCCACC-3¢, corresponding to nucleotides )3308 to
)3287) and the antisense primer Kin111 (5¢-dAGAGAC
GCGTCTGTAATCCAGCTACTCGGGAG-3¢, corres-
ponding to nucleotides )2003 to )1980). Promoter 3
fragment using the sense primer Kin112 (5¢-dGA
GAGGTACCCAGGATGGTCTCGATCTCCTGAC-3¢,
corresponding to nucleotides )1394 to )1373) and the
antisense primer Kin113 (5¢-AGAGACGCGTGGCT
CCGGAGCCCTGAGGGATC-3¢, corresponding to
nucleotides )21 to )1). In each case, sequences underlined
in the sense and antisense primers correspond to KpnI and
MluI sites, respectively. The amplified gene fragments
containing Promoter 1–3 sequences were digested with
KpnI and MluI and were subcloned into pGL3 Basic and
pGL3 Enhancer vectors to generate the recombinant
plasmids pGL3b:Prm1; pGL3b:Prm2 and pGL3b:Prm3,
each in pGL3Basic and pGL3e:Prm1; pGL3e:Prm2 and
pGL3e:Prm3, each in pGL3Enhancer. The fidelity of all
recombinant plasmids was verified by restriction endonuc-
lease mapping and by DNA sequence analysis.
Assay of luciferase activity
HEK 293 cells were plated in Eagle’s minimum essential
medium, 10% fetal bovine serum in six well dishes at
1 · 105 cells per well. At 70–80% confluence, cells were
cotransfected with recombinant pGL3 Basic or pGL3
Enhancer control vector, encoding firefly luciferase, or their
recombinant derivatives (0.4 lg per well) along with pRL
TK (50 ng per well) using Effectene (Qiagen), encoding
Renilla luciferase, as recommended by the supplier. Forty-
eight hours after transfection, cells were washed in phos-
phate buffered saline (NaCl/Pi), harvested in 350 lL
Reporter Lysis Buffer (Promega) and centrifuged at
14 000 g for 1 min at room temperature.
HEL 92.1.7 cells were transfected using the DMRIE-C
transfection reagent, essentially as described by the supplier
(Life Technologies, Inc). Briefly, 0.5 mL of serum free
RPMI 1640 medium was dispensed into a six-well dish and
6 lL of DMRIE-C reagent was added. Thereafter, 0.5 mL
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of serum free RPMI 1640 medium containing 2 lg of
recombinant pGL3 Basic or pGL3 Enhancer vectors and
200 ng of pRL-TK was added and DNA/DMRIE-C
reagent was complexed by incubation at room temperature
for 30 min. Thereafter, 0.2 mL of serum free RPMI 1640
medium containing 2 · 106 HEL 92.1.7 cells were added to
the complex followed by incubation for 4 h (37 C in a CO2
incubator) after which 2 mL of RPMI 1640 medium
containing 15% fetal bovine serum was added. Forty-eight
hour after transfection, the cells were washed in NaCl/Pi,
harvested in 100 lL Reporter Lysis Buffer (Promega) and
were centrifuged at 14 000 g for 1 min at room temperature.
HEK 293 and HEL 92.1.7 cell supernatants were assayed
for both firefly and renilla luciferase activity using the
reagents from the Dual Luciferase Assay SystemTM. Briefly,
100 lL of firefly luciferase assay reagent was predispensed
into the required number of luminometer tubes, to these,
20 lL of cell lysate was added and luminescence measured
for 10 s following a 2-s premeasurement delay in a Turner
luminometer (TD-20/20). Subsequently 100 lL of the Stop/
Glo Reagent TM was added and luminescence due to renilla
luciferase was measured. Relative firefly to renilla luciferase
activities were calculated as a ratio and were expressed in
relative luciferase units (RLU).
Bioinformatic analysis
The complete nucleotide sequence of the TP gene and
flanking sequences on human chromosome 19 is available
at http://www.ncbi.nlm.nih.gov, accession no. AC005175.
The nucleotide sequence corresponding to accession no.
AC005175 is 41 303 bp and contains the reverse comple-
ment of the TP coding sequence from nucleotides
5¢ 11127–24481 3¢. For bioinformatic analysis, the reverse
complement of nucleotides 5¢ 11127–24481 3¢ were
obtained to generate the sequence 5¢ )9500 to +3854 3¢
(i.e complementary to 5¢ 11127–24481 3¢) where the
translational start site (ATG) corresponds to nucleotide
+1. Thereafter, sequences immediately 5¢ of the ATG, i.e.
nucleotides )1399 to +1 were analyzed for putative
transcription factor binding sites and regulatory elements
using the Matinspector ProfessionalTM program [23]
available at http://genomatix.gsf.de/cgi-bin/matinspector/
matinspector.pl. All programs were used at the default
settings.
Statistical analysis
Statistical analysis of differences were analyzed using
the two-tailed students unpaired t-test. All values are
expressed as mean ± standard error of the mean (SEM).
P values £ 0.05 were considered to indicate statistically
significance differences.
R E S U L T S
Identification of the major TP mRNA transcripts
and determination of their transcription
initiation sites
The organization and the exon-intron boundaries of the
human thromboxane (TX) A2 receptor (TP) gene and the
theoretical range of putative TP mRNA transcripts are
illustrated in Fig. 1. In this study, in view of the reported
discrepancies in the patterns of exon usage and the presence
of multiple transcription initiation (TI) sites within the
human TP gene [4,6,7], the initial aim was to characterize
the major TP mRNA transcripts with respect to their
5¢ UTR sequences and to identify the major TI sites in the
megakaryocyte HEL 92.1.7 and in the trophoblast TM-1
cell lines, both of which have been confirmed to express TP
mRNA at high levels [17].
To identify the major TP mRNA transcripts, a RT-
PCR based approach was utilized employing total RNA
isolated from HEL 92.1.7 cells as a template. The strategy
adopted and relative positioning of the primers used are
illustrated in Fig. 2A. Following RT-PCR analysis with
the E1 primer Kin129 and the antisense primer Kin2, a
single 268 bp product was amplified (Fig. 2B, lane 2) and
characterized by nucleic acid sequence analysis (data not
shown) and was confirmed to represent sequences due to
splicing between E1-E2 sequences. No product containing
E1-E1b-E2 sequences was amplified. Similarly, following
RT-PCR analysis with the sense primer Kin130 and the
antisense primer Kin2, a 270 bp product was amplified
(Fig. 2B, lane 1) and subjected to nucleic acid sequence
analysis (data not shown) and was confirmed to represent
sequences due to splicing between E1b-E2 sequences. In
addition to the correct amplification product correspond-
ing to predicted E1b-E2 sequences, a minor RT-PCR
product of higher molecular weight (700 bp) was also
amplified but was confirmed to represent nonspecific
artifactual sequence. Thus, these data demonstrate that
whereas the major TP mRNA transcripts contain either
E1-E2 or E1b-E2 sequences, there was no evidence of a
TP transcript containing E1-E1b-E2 sequences
(Fig. 2C,D) and these data correlate with findings in the
trophoblast TM-1 cell line (data not shown)
Thereafter, a 5¢RACE approach was adopted to identify
the TI sites of the TP mRNA transcripts in HEL 92.1.7 and
TM-1 cells, as outlined in Fig. 3A. Following subcloning of
the resultant nested 5¢ RACEproducts and their subsequent
nucleotide sequence analysis, multiple TI sites clustered
around)92 to)115 within E1were identified inHEL 92.1.7
cells (Fig. 3B). Furthermore, two additional transcription
initiation sites were located at )99 within E1b (Fig. 3B).
Consistent with this, in TM-1 trophoblast cells, themajor TI
sites were identified around )94 and )114, within E1, and a
TI site was also identified within E1b at )99 (Fig. 3C).
Thus, taken together, these data indicate that there are two
major types of TP transcripts that are distinguishable on the
basis of their differential utilization of either E1 or E1b
sequences; moreover, 5¢ RACE confirmed that there are
multiple TI sites within both HEL 92.1.7 cells and TM-1
cells with the major TI sites clustered at sites within E1 and
E1b.
Analysis of 5¢ UTR of TPa and TPb
Previous studies have demonstrated substantial variations
in the relative levels of expression of TPa and TPbmRNAs
in a variety of human tissues; whereas TPa mRNA levels
remains constant between cell types, the levels of TPb vary
considerably indicating that their expression may be inde-
pendently regulated [17]. Additionally, the presence of two
putative promoters, P1 and P2, raised the possibility that
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TPa and TPb expression may be regulated by alternative
promoter utilization. Hence, to ascertain whether the TP
isoforms may be subject to alternative promoter utilization,
we sought to initially identify the 5¢ UTR sequences
associated with the individual TPa and TPb mRNAs and
thereafter, to identify the major TI sites of those isoform
specific transcripts.
Initially, to identify the 5¢UTR sequences found on TPa
and TPb mRNAs, an RT-PCR approach was employed
using 5¢ sense primers based on E1 or E1b sequences and 3¢
antisense primers that distinguish TPa from TPb sequences
using RNA isolated from HEL 92.1.7 cells as a specific
template (Fig. 4A). RT-PCR analysis with the E1 primer
Kin129 and the TPa specific primer Kin75 generated a
1319 bp product (Fig. 4B, lane 1) that was confirmed, by
Southern blot analysis (Fig. 4C, lane 1) and nucleotide
sequence analysis (data not shown), to represent sequences
due to splicing between E1:E2:E3 sequences. Additionally,
RT-PCR analysis with the E1b primer Kin130 and the TPa
specific primerKin75 generated a 1321 bp product (Fig. 4B,
lane 3) that was confirmed, by Southern blot analysis
(Fig. 4C, lane 3) and nucleotide sequence analysis (data not
shown), to correspond to sequences due to E1b:E2:E3
splicing. In striking contrast, RT-PCR analysis with either
Kin129 or Kin130 vs. the TPb specific antisense primer
Kin21 failed to result in the amplification of the predicted
1188 bp product (Fig. 4B,C, lane 2) or of the predicted
1190 bp product (Fig. 4B,C, lane 4), respectively. Hence, it
Fig. 1. Organization of the human TP gene including potential TP mRNA transcripts. (A) The human TP gene contains three exons E1, E2 and E3
separated by two introns I1 and I2. An additional exon, E1b, is located within I1 and there are two putative promoters P1 and P2, located 5¢ of E1
and E1b sequences, respectively. The lower numbering system indicates the position of those sequences within the TP gene, spanning from )8500 to
+6547 (italics, underlined) while the upper numbering system indicates the position of the exons sequences within the TP mRNA(s) (bold). All
nucleotide numbers are assigned relative to the translation start site, ATG designated+1 and all sequences 5¢ of +1 are given a – designation and
all numbers 3¢ of +1 are given a + designation. E1, encodes nucleotides )289 to )84 of 5¢ untranslated region (UTR) of the TP mRNA;
alternatively, exon E1b, of 115 bp, located within I1 encodes )199 to )84 of 5¢ UTR sequence. E2 contains nucleotides )83 to )1 of 5¢ UTR
sequence and+1 to+786 of coding sequence, encoding amino acids 1–261. E3 contains nucleotides+787 to+1029, coding for amino acids 262–
343 of TPa, and nucleotides +1030 to +1938, representing 3¢ UTR sequences. Nucleotides +984 to +1642 behave as a potential intron (Intron
3b) on the TPmRNA; splicing of nucleotides+983/+1643 generates a mRNAwhich has a novel open reading frame, encoding TPb of 407 amino
acids, whereby nucleotides +983 to +1221 encode amino acids 328–407 that are unique to TPb. (B–D) In theory, depending on the differential
utilization of E1 and/or E1b sequences, the TP gene may be transcribed to generate three putative, alternatively spliced mature mRNAs, namely
E1-E2-E3 (Panel B), E1b-E2-E3 (Panel C) and E1-E1b-E2-E3 (Panel D), that differ within their 5¢ UTR sequences. Additionally, further alternative
splicing of the latter TP transcripts within E3 may potentially double the number of TP transcripts to six, depending on the presence (TPa
transcripts) or absence (TPb transcripts) of intron 3b (+ 983/+1643) sequences.
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appears that the TPa, but not the TPb, mRNA contains E1
and E1b sequences.
To further characterize the 5¢ UTR of the TP mRNA
transcripts, RT-PCRanalysis was performed using the sense
primerKin45 (Fig. 4A) in combinationwith theTPa specific
antisense primer Kin75 or the TPb specific antisense primer
Kin21. While RT-PCR analysis with the E2 sense primer
Kin45 and the TPa specific primer Kin75 produced a
fragment of 1163 bp (Fig. 4B, lane 5) thatwas confirmed, by
Southern blot analysis (Fig. 4C, lane 5) and nucleotide
sequence analysis (data not shown), to representTPa specific
sequences, RT-PCR analysis with Kin45 and the TPb
specific primer Kin21 failed to result in the amplification of
the expected 1032 bp product (Fig. 4B,C, lane 6). Thus, it
appears that while nucleotides 5¢ of )40 to )24 within E2
were present on the TPa mRNA transcript, this region was
actually not present on the TPbmRNA transcript (Fig. 4C)
indicating that TPa and TPb mRNA sequences diverge at
5¢ UTR sequences within E2. However, despite the latter
finding, consistentwith ourprevious reports [17], the positive
expressionofmRNAencodingTPb sequences inHEL92.1.7
cellswas indeedconfirmedbyRT-PCRanalysisusinga sense
primer Kin6 and the TPb-specific antisense primer Kin21
wherebyaproductof990 bpwasamplifiedandconfirmedby
nucleotide sequence (Fig. 5B,C, lane 10).
Thereafter, to ascertain the precise point of divergence
between TPa and TPb mRNAs within their 5¢ UTR
regions, two additional sense primers, Kin47, corresponding
to nucleotides )27 to )11 within E2, and Kin46 corres-
ponding to nucleotides )12 to +5 within E2 were analyzed
in combination with TPa (Kin75) and TPb (Kin21) specific
antisense primers (Fig. 5A). RT-PCR analysis using the
sense primers Kin46 or Kin47 vs. the TPa specific antisense
primer Kin75 resulted in the amplification of TPa specific
products of 1134 bp and 1150 bp, respectively (Fig. 5B,
lane 1 & 3) that were confirmed by Southern blot analysis
(Fig. 5C, lane 1 & 3) and nucleotide sequence analysis (data
not shown) to represent TPa specific sequences. Using the
TPb specific primer, Kin21, while RT-PCR analysis using
the primer Kin47 did not result in the amplification of the
predicted TPb specific product of 1019 bp (Fig. 5B,C, lane
4), RT-PCR analysis using the primer Kin46 did result in
the amplification of a TPb specific product of 1003 bp
(Fig. 5B, lane 2) that was confirmed by Southern blot
analysis (Fig. 5C, lane 2) and by nucleotide sequence
analysis (data not shown) to represent TPb specific
sequences. Similar findings were also shown to occur in
TM-1 trophoblast cells and in vascular smoothmuscle (data
not shown), thus ruling out the possibility of tissue specific
splicing events. To establish that the primer pairs Kin47/21
Fig. 2. Arrangement of noncoding exons in the 5¢ UTR of the TP transcripts. (A) Relative positioning of the two sense oligonucleotide primers
Kin129 andKin130 and the antisense primer Kin2 used for the analysis of the 5¢ UTR sequences of TPmRNAs. (B) Agarose gel electrophoresis of
RT-PCR products (7 lL per lane) derived fromHEL 92.1.7 first strand cDNA templates: lane 1, E1b-E2, 270 bp product vs. primers Kin130/Kin2;
lane 2, E1-E2, 268 bp product vs. primers Kin129/Kin2; lane 3, GAPDH, 983 bp product vs. GAPDH forward (Gf) and GAPDH reverse (Gr)
primers; lanes 4–6, negative control PCR reactions carried out in the absence of template first strand cDNA in the presence of primersKin130/Kin2,
Kin129/Kin2 andGf/Gr, respectively; laneM, pGEMDNAmarkers. The correctly sizedKin130/Kin2 andKin129/Kin2 generated PCR fragments
are indicated by the arrow. (C and D) Schematic representation of the RT-PCR products, and their corresponding nucleotide sequences, generated
using primers Kin129/Kin2 and Kin130/2, respectively. The gap 3¢ of nucleotide +72 within E2 indicates the position at which the nucleotide
sequence of the RT-PCR product generated with Kin2 terminates.
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were indeed functional, the previously described plasmid
construct pBluescript II KS(–):TPb [4] containing a 1.5 kb
EcoRI insert encoding the full-length coding sequence (+1
to +1224) for TPb plus an additional 5¢ (212 bp), corres-
ponding to TPa 5¢ UTR sequences, and 3¢ (69 bp) UTR
was used as a positive control. Following PCR analysis
Fig. 3. Determination of the transcription initiation sites for the TP gene. (A) Relative positioning of the oligonucleotide primers used for the
amplification of the 5¢UTR of TP mRNA transcripts. The TP specific primer Kin60 was used to direct first strand cDNA synthesis. Following the
addition of a homopolymeric dC tail to the first strand cDNA using deoxynucleotidyl transferase, primary PCR amplifications were performed
using the anchor primer, AAP, in conjunction with the TP-specific primer, Kin2. Thereafter, nested (2) amplifications were performed with the
sense abridged universal anchor primer, AUAP, in combination with the TP-specific antisense primer Kin3. Following subcloning of the secondary
amplification products, nucleotide sequence analysis of the amplification products was performed. (B) Location of themajor transcription initiation
(TI) sites within E1 and E1b using RNA isolated from HEL 92.1.7 cells as a template. (C) Location of the major TI sites detected in trophoblast
TM-1 cells. The TI number assigned to each transcript is indicated relative to the translation start site, designated +1, and are consistent with
splicing of either E1 ()84) or E1b ()84) to E2 ()83).
Fig. 4. Analysis of differential 5¢ UTR utilization by TP mRNA transcripts. (Panel A) Relative positioning of the oligonucleotides primers (fi) and
radiolabelled probes (–r) used to characterize the 5¢UTR of the TPa and TPbmRNA transcripts. To specifically amplify TPamRNA transcripts,
the antisense primer Kin75 was used in conjunction with either the E1-specific sense primer, Kin129, the E1b-specific sense primer, Kin130 or the
E2-specific primer, Kin45. Similarly, to specifically amplify TPb mRNA transcripts, the TPb-specific antisense primer Kin21 was used in con-
junction with either Kin129, Kin130 or Kin45. (B) Agarose gel electrophoresis of RT-PCR products (7 lL per lane) derived fromHEL 92.1.7. First
strand cDNA templates: lane 1, Kin129/Kin75 predicted to amplify 1310 bp TPa fragment containing E1 and E2; lane 2, Kin129/Kin21 predicted
to amplify 1188 bp TPb fragment containing E1&E2; lane 3, Kin130/Kin75 predicted to amplify 1321 bp TPa fragment containing E1b&E2; lane
4, Kin130/Kin21 predicted to amplify 1190 bp TPb fragment containing E1b & E2; lane 5, Kin45/Kin75 predicted to amplify 1040 bp TPa
fragment containing E2; lane 6, Kin45/Kin21, predicted to amplify 899 bp TPb fragment, containing E2; lane 7, GAPDH, 983 bp product vs.
primers Gf/Gr; lane 8, RT-PCR negative control in the absence of RT for the primer pairs Kin129/Kin75; lane M, pGEM DNA markers. (C)
Southern blot analysis of the RT-PCR products (B, lanes 1–8) using a P32 radiolabelled TP specific probe, Kin46 and a GAPDH probe, Kin119
(specific for the +552 to +570 region of GAPDH).
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using the primer pair Kin47/21 or positive control primers
Kin46/21, correct size amplification products of 1019 and
1004 bp, respectively, were amplified (Fig. 5, panels C and
D, lanes 8 and 9, respectively), thus ruling out the possibility
that the primer pair may be nonfunctional.
Taken together these data suggest that in addition to their
widely recognized sequence differences due to the presence
(TPa mRNA) or absence (TPb mRNA) of Intron 3b
sequences within E3, the TPa and TPb mRNA sequences
also diverge at )12 within E2. Moreover, while E1 and/or
E1b sequences in addition to E2 sequences 5¢ of )12 are
found associated with TPamRNA transcripts, they are not
found associated with TPb mRNA sequences.
Identification of the TI site of the TPb mRNA transcript
The sequence divergence of TPb from TPa mRNAs at )12
within E2 could be explained by either the presence of a TI
site for the TPb mRNA transcript at )12 or due splicing of
nucleotides elsewhere in the 5¢ flanking region of the TP
gene to nucleotides located within the )12 region of TPb
mRNA transcripts, giving rise to a novel 5¢ UTR for the
TPb mRNA transcript. Therefore, to identify the TI site of
TPb, two alternative 5¢ RACE approaches were employed,
as outlined in Fig. 6A. In the first approach, two TPb
specific primers were utilized. Specifically, total HEL 92.1.7
cell RNA was converted to 1 CDNA using the primer
Kin58. Following dC-tailing, primary amplification was
performed using the primer AAP in combination with the
TPb-specific antisense primer, Kin21. Nested amplification
was then performed using the sense primer AUAP in
combination with the TP-specific primer, Kin60 (Fig. 6A).
Following subcloning and nucleotide sequence analysis of
the 5¢ RACE products, a number of independent TPb
specific transcripts with a TI site at )12 were identified
(Fig. 6B). No transcripts with TP sequences 5¢ of )12 were
identified. However, a number of transcripts containing TI
sites within the coding region of E2 were also noted; these
transcripts are most likely the result of incomplete reverse
transcription as a consequence of the large distance,
1000 bp, between the first strand cDNA primer, Kin58
and the putative 5¢ terminus of the TPb mRNA transcript
(data not shown).
Thereafter, employing a second 5¢ RACE approach to
confirm our data and also to eliminate the problem of
premature termination of first strand cDNA synthesis,
nested amplification products were subjected to differential
hybridization using the primers Kin46 and Kin47, corres-
ponding to sequences 3¢ and 5¢ of the )12 divergent region
within TPa/TPb mRNAs, respectively, as discriminatory
hybridization probes (Fig. 6A). Following nucleotide se-
quence analysis of Kin46+Kin47–transcripts, a number of
independent clones with TI sites at)12 (two clones) and)15
(three clones) were identified (Fig. 6B). No transcripts with
TP sequences 5¢ of )12 were identified. These results
demonstrate that whereas the TI site of TPa occurs within
E1 and/or E1b, the TI site of TPb occurs at )15 to )12. As
neither E1 nor E1b were present on the TPb mRNA
transcript, this also suggests that neither P1 nor P2 are
regulating the expression of TPb. Moreover, the identifica-
tion of a TI site for the TPb mRNA transcript occurring at
)12 to )15 within E2 suggests that TPb mRNA expression
may be regulated by a novel putative promoter, arbitrarily
termed P3, most likely located 5¢ of )12.
Functional analysis of the 5¢ flanking region
of the TPb mRNA transcript
Thereafter, we sought to assess the ability of a gene
fragment encoding the nucleotides )1394 to )1, immedi-
ately flanking the divergent )12 region between TPa/TPb
transcripts, to direct the basal transcription of luciferase
activity in genetic reporter assays. As comparative controls,
gene fragments encoding the previously described P1, 5¢ of
Fig. 5. Analysis of the differential 5¢ UTR utilization of the TP mRNA transcripts within exon 2. (A) Relative positioning of the oligonucleotides
primers (fi) and radiolabelled probes (–r) used for the analysis of the 5¢ UTR of TPa and TPb mRNAs. (B) Agarose gel electrophoresis of RT-
PCR products (7 lL per lane) derived from HEL 92.1.7. First strand cDNA templates (lanes 1–7 and lane 10) and pBluescript II KS(–):TPb [4]
(lanes 8–9): lane 1, Kin46/Kin75 predicted to amplify a 1134 bp fragment; lane 2, Kin46/Kin21 predicted to amplify 1003 bp fragment; lane 3,
Kin47/Kin75 predicted to amplify 1150 bp fragment; lane 4, Kin47/Kin21 predicted to amplify 1019 bp fragment; lane 5, GAPDH, 983 bp product
vs. primers Gf/Gr; lanes 6–7, RT-PCR negative controls in the absence of RT in the presence of the primer pairs Kin46/Kin75 and Kin46/Kin21,
lane 8, Kin47/21 predicted to amplify a 1019 bp fragment; lane 9, Kin46/21 predicted to amplify 1004 bp fragment, respectively; lane 10, Kin6/21
predicted to amplify 990 bp fragment; lane M, pGEMDNAmarkers. (C) Southern blot analysis of the RT- PCR products (B, lanes 1–10) using a
P32 radiolabelled TP specific probe (Kin2) and a GAPDH probe (Kin119).
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E1 [6] and P2, 5¢ of E1b [4] were also assessed for their
ability to direct transcription and expression of luciferase
(Fig. 7A). Additionally, as negative controls, the promoter-
less pGL3b and pGL3e vectors were assessed for their
ability to direct transcription and expression of luciferase.
Routinely, 0.09 ± 0.01 and 0.31 ± 0.10 RLU were
obtained for the empty pGL3b and pGL3e vectors,
respectively. The plasmid pGL3b:Prm1 directed high level
of luciferase activity in both HEL and HEK 293 cells
(Fig. 7B) consistent with high basal transcription from P1
sequences in both cell types. Additionally, the presence of
the SV40 enhancer sequence located downstream of the
luciferase gene in the recombinant plasmid pGL3e:Prm1
greatly increased the level of basal luciferase transcription
under the control of P1 in both HEL 92.1.7 and HEK 293
cells (Fig. 7B). It was noteworthy that while the level of
basal P1 transcriptional activity was significantly lower in
HEK 293 cells than in HEL 92.1.7 cells (P ¼ 0.0035) when
expressed in pGL3b:Prm1, this effect was negated when P3
was expressed in pGL3e:Prm1 (Fig. 7B).
The ability of P2 to direct basal transcription of the
luciferase gene was also investigated. Transfection of the
plasmid pGL3b:Prm2 directed low levels of luciferase
expression in both HEL cells or in HEK 293 cells
(Fig. 7C), consistent with the low basal transcriptional
activity associated with P2. However, in the presence of
the SV40 enhancer, the recombinant plasmid
pGL3e:Prm2 did mediate significant increases in basal
luciferase expression confirming that P2 may indeed
function as a promoter in both HEL 92.1.7 cells and also
in HEK 293 cells (Fig. 7C), albeit with substantially
weaker activity than P1 in both cell types (Fig. 7B).
While there was no difference in the level of basal P2-
directed transcription when expressed in pGL3b:Prm2,
the level of P2 activity in HEK 293 cells was significantly
lower than in HEL cells when P2 was expressed in
pGL3e:Prm2 (P ¼ 0.0166).
Thereafter, we examined the ability of the gene fragment
()1394 to +1) encoding a possible putative promoter,
arbitrarily termed P3, located immediately 5¢ of the
translational start site/divergent )12 region between TPa
and TPb to direct expression of luciferase activity. Trans-
fection of the plasmid pGL3b:Prm3 into both HEL 92.1.7
cells and HEK 293 cells did lead to significant increases in
the basal expression of luciferase activity in both cell types
(Fig. 7D). Moreover, in the presence of the SV40 enhancer,
transfection of the plasmid pGL3e:Prm3 did result in
substantial increases in luciferase expression in both HEL
cells and HEK 293 cells (Fig. 7D). It was noteworthy that
there were no significant cell-dependent differences in the
basal transcriptional activity of P3 between either HEL
92.1.7 or HEK 293 cells when expressed in either
pGL3b:Prm3 or in pGL3e:Prm3. Taken together, these
data not only confirm the functional activity associated with
the well characterized P1, but also indeed confirm activity
associated with P2 in both HEL 92.1.7 and HEK 293 cells.
Moreover, they strongly support the existence of a novel
promoter, P3, immediately 5¢ of the translational start site
and, in view of our previous data presented herein, suggest
that P3 may direct expression of TPb.
Effect of PMA on TP mRNA expression
Thereafter, in order to identify regions that may be
important for promoter activity, the nucleotide sequence
encoding the P3 gene fragment (spanning )1394 to+1) was
analyzed for both transcriptional and regulatory sequence
elements using the Matinspector ProfessionalTM bioinfor-
matics programme [23]. P3 sequences were found to lack
typical TATA or CAAT boxes (Fig. 8), similar to that
Fig. 6. Identification of the transcription initiation (TI) sites of the TPb transcripts using 5¢ RACE analysis. (A) Relative positioning of the
oligonucleotides (fi) used for 5¢ RACEamplification and radiolabelled probes (–r) used for Southern blot analysis. The TPb-specific primerKin58
(spanning across the splice site) was used to direct first strand cDNA synthesis using RNA from HEL 92.1.7 cells as template. Following the
addition of a homopolymeric dC tail to the first strand cDNA template, primary PCR amplifications were performed using the AAP primer
in conjunction with the TPb-specific primer, Kin21. Thereafter, secondary amplifications were performed with AUAP in combination with the
TP-specific antisense primer Kin60. Following subcloning of the secondary amplification products, nucleotide sequence analysis of the amplifi-
cation products was performed to identify the major TI sites (B). As an alternative, the TP primer Kin51 was used to direct first strand cDNA
synthesis. Following the addition of a homopolymeric dC tail to the first strand cDNA template, primary PCR amplifications were performed using
the AAP primer in conjunction with the TP-specific primer, Kin60. Thereafter, secondary amplifications were performed with AUAP in combi-
nation with the TP-specific primer Kin2. Using the latter approach, a library of secondary amplification products was generated and screened with
P32 labelled Kin46 and Kin47 probes. (B) TI sites of Kin46+, Kin47– clones following nucleotide sequence analysis.
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previously identified for P1 and P2 sequences [4]. Consensus
sequences for serum response element binding protein
(SREB) and Oct-1 transcription factor binding sites were
identified at )675 and )107, respectively (Fig. 8). Addition-
ally, a number of consensus sequences were predicted for
phorbol myristic acid (PMA)-responsive transcription
factors, including an AP-4 site located at )1005, two AP-1
sites at )236 and )27 and an SP-1 site at )670 (Fig. 8).
Previous studies have established that exposure of HEL
92.1.7 cells to PMA resulted in an increase in TP mRNA
expression and yielded an overall increase in TP protein
expression [5], possibly mediated through a phorbol
response element locatedwithin P1, but not in P2. D’Angelo
et al. [7] later proposed that the major PMA response
element within the TP gene is actually located within a Sp1
site 5¢ to E1. However, these studies did not discriminate
between TPa and/or TPb mRNA expression. Thus, to
investigate whether P3 transcriptional activity may be
responsive to PMA treatment, we investigated the effect
of PMA stimulation in HEL 92.1.7 cells transiently
transfected with pGL3b:Prm3/pGL3e:Prm3 comparing it
to that which occurred with corresponding reporter vectors
encoding the well characterized PMA-responsive P1 [7] and
the non-PMA responsive P2 (Fig. 9A–C). Pretreatment of
HEL 92.1.7 cells with PMA resulted in 1.7- and 1.6-fold
augmentations in luciferase expression in cells transfected
with pGL3b:Prm3 and pGL3e:Prm3, respectively (Fig. 9C;
P £ 0.05). As a positive control, pretreatment of HEL
92.1.7 cells with PMA resulted in a 2.75- and 2.66-fold
augmentation in cells transfected with pGL3b:Prm1 and
pGL3e:Prm1, respectively (Fig. 9A; P £ 0.003). In con-
trast, pretreatment of HEL 92.1.7 cells transfected with
either pGL3b:Prm2 and pGL3e:Prm2 with PMA did not
alter P2-mediated luciferase activity relative to vehicle-
treated cells (Fig. 9B). As an additional control, the effect of
PMA on the ability of the promoterless pGL3b and pGL3e
vectors to direct transcription and expression of luciferase
was assessed. Routinely, 0.10 ± 0.02 and 0.29 ± 0.10
RLU were obtained for the empty pGL3b and pGL3e
vectors, respectively, in the presence of PMA. When
compared to non-PMA treated vectors, no significant
alteration in basal RLU levels was detected (P > 0.70).
To establish whether PMA has an effect on TPb mRNA
expression levels, a previously described semiquantitative
RT-PCR based approach was utilized [17], whereby TPa
mRNA levels were used as a reference control [5]. RT-PCR
analysis was performed using a common TP sense primer
(Kin16) in combination with discriminatory TPa (Kin75)
and TPb (Kin21) based antisense primers, essentially as
previously described [17]. Correlating with previous findings
[17], both TPa and TPb mRNAs were expressed in HEL
92.1.7 cells (Fig. 9D). Exposure of HEL 92.1.7 cells to PMA
Fig. 7. Functional analysis of the 5¢ flanking region of the TP receptor gene. (A) Schematic of the TP genomic region spanning nucleotides )8500 to
+786, encoding promoter P1, P2 and P3 in addition to E1, E1b andE2 sequences and intronic sequences. The lower and upper coordinates are used
to compare the genomic position of E1, E1b andE2with their locationwithin the TP transcripts, respectively. Threemajor gene fragments encoding
Promoters 1 ()8500 to )5895), Promoter 2 ()3308 to )1979) and Promoter 3 ()1394 to )1) sequences were subcloned into the luciferase reporter
vectors pGL3 Basic (pGL3b) and pGL3 Enhancer (pGL3e) to generate the recombinant plasmids pGL3b:Prm1, pGL3b:Prm2, pGL3b:Prm3,
pGL3e:Prm1, pGL3e:Prm2 and pGL3e:Prm3. (B) The plasmids pGL3b:Prm1 (P1b), pGL3e:Prm1 (P1e), encoding firefly luciferase under the
control of P1, were cotransfected with pRLTK intoHEL 92.1.7 cells andHEK 293 cells. (C) The plasmids pGL3b:Prm2 (P2b), pGL3e:Prm2 (P2e),
encoding firefly luciferase under the control of P2 were cotransfected with pRL TK into HEL 92.1.7 cells and HEK 293 cells. (D) The plasmids
pGL3b:Prm3 (P3b), pGL3e:Prm3 (P3e), encoding firefly luciferase under the control of P3 were cotransfected with pRL TK into HEL 92.1.7 cells
and HEK 293 cells. Thereafer, firefly and renilla luciferase activity was assayed and results are expressed as mean relative luciferase activity, in
arbritary units (RLU), ± SEM (n ¼ 6).
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(100 nM; 6 h) resulted in a 1.41-fold increase in TPbmRNA
expression when compared to vehicle-treated HEL 92.1.7
cells (TPb/GAPDH densitometric ratios of 0.29 ± 0.07
and 0.41 ± 0.07 in normal and PMA-treated HEL 92.1.7
cells, respectively). Expression of PMA-responsive control
TPamRNA expression was increased by 1.3-fold compared
to control vehicle-treated HEL 92.1.7 cells (TPa/GAPDH
densitometric ratios of 0.52 ± 0.10 and 0.67 ± 0.06 in
control non-PMA treated and PMA-treated HEL 92.1.7
cells, respectively). Taken together, these data suggest that a
novel promoter region, termed P3, exists 5¢ of the TI site of
TPb, within intron 1. Bioinformatic analysis suggests the
presence of key signature transcription factor binding site,
including a number of potential PMA-responsive elements,
such as AP-1, AP-4 and SP-1 transcription factor binding
sites. Genetic reporter assay confirm that P3 can direct basal
expression of luciferase activity in HEL and in HEK 293
cells and that P3 is responsive to PMA-treatment in HEL
cells. Coincident with this, expression of TPb mRNA is
up-regulated in response to PMA treatment.
D I S C U S S I O N
Whereas the main physiologic actions attributed to TXA2 is
its role in vascular hemostasis [24], it can induce diverse
cellular responses including constriction of vascular and
bronchial smooth muscle cells [25], potentiation of the
mitogenic and hypertrophic growth of vascular smooth
muscle cells [26–28], contraction of glomerular mesangial
cells and intrarenal vascular tissue decreasing glomerular
filtration rates [29], stimulation of apoptosis of immature
thymocytes [30]. TXA2 has been implicated as a mediator of
a number of vascular disorders including thrombosis,
unstable angina, myocardial infarction, pregnancy-induced
hypertension, bronchial asthma and glomerulonephritis
[1,29,29,30]. Patients with acute myocardial infarction have
increased numbers of platelet TXA2 receptors (TPs) and
receptor number is greatest in patients with prolonged
ischemic chest pain [33]. Mice deficient in TXA2 receptors
display mild bleeding dysfunction and exhibit diminished
responses to vascular stimuli [34]. Moreover, there is
substantial evidence that TXA2 may mediate the actions
of the isoprostane 8-epi prostaglandin (PG) F2a, generated
in abundance in situations of oxidative stress [35,36].
In humans, but not in other species thus far investigated,
TXA2 signals through two TP isoforms, TPa and TPb [2,3],
that arise by differential splicing [3,4]. Whereas both TPa
and TPb display indistinguishable coupling to phospho-
lipase (PL) Cbmembers, the main signalling pathway of TP
[1,11,12], they oppositely regulate adenylyl cyclase activity
[8] and TPa, but not TPb, mediates-agonist activation ofGh
leading to PLC activation [9]. Additionally, TPb, but not
Fig. 8. Bioinformatic analysis of the genomic sequence containing Promoter 3 and the 5¢ UTR within E2. Bioinformatic analysis of the genomic
sequence of the TP gene, spanning from +1 to )1399, encoding the promoter 3 gene fragment, was performed as described under Experimental
procedures. Using Matinspector ProfessionalTM, bioinformatics programme [23], no typical TATA or CAAT boxes were predicted. A number of
consensus transcription factor binding sites were predicted, namely an AP-4 site located at )1005, two AP-1 sites located at )236 and )27, a SP-1
site located at )670, a serum response element binding protein (SREB) located at )675 and an Oct-1 transcription factor binding site predicted at
)107. The arrow indicates the position of the transcription initiation (TI) sites of the TPbmRNA transcript as predicted by 5¢ RACEanalysis where
the translation start site, designated +1, is highlighted in bold.
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TPa, is subject to agonist induced internalization leading to
its down-regulation following prolonged exposure to the TP
agonist, U46619 [15,16]. Both TP isoforms mediate activa-
tion of the extracellular signal regulated protein kinase and
stress activated protein kinase families of the mitogen
activated protein kinase cascades in response toU46619 and
the isoprostane 8-epi PGF2a [19,37]. In studies investigating
cross-talk between TXA2 and other prostanoids, we have
established that signalling by TPa, but not TPb, is subject to
prostacyclin and PGD2-mediated desensitization involving
direct protein kinase A phosphorylation of TPa within its
unique C-tail [12,13]. These studies imply an essential role
for TPa in vascular hemostasis and, possibly, a redundant
role of TPb in this essential process. In addition, both TPa
and TPb are subject to protein kinase C-mediated desen-
sitization by the EP1 isoform of the PGE2 receptor family;
however, TPa is significantlymore sensitive than TPb to this
desensitization [14].
Thus, while the biologic relevance for the existence of two
TP receptors in humans is unknown, these data provide
compelling evidence that the individual TP isoforms have
distinct physiologic/pathophysiologic roles. Consistent with
this view, it appears that the TPa andTPb are also subject to
differential expression [17,18]. The molecular basis of this
differential TP expression is unknown but suggests that the
TP receptors may not only be the products of differential
splicing but are also subject to differential gene regulation.
The presence of two promoters, P1 and P2, on the single TP
gene raises the possibility that the TPa and TPb isoforms
may be under the transcriptional control of distinct
promoters [4].
The structure of the human TP gene was first elucidated
by Nu¨sing et al. [4] and was proposed to contain three
major exons, E1, E2 andE3with an additional 115 bp exon,
designated E1b, identified between E1 and E2 within intron
(I) 1 (Fig. 1A). The two individual promoters P1 and P2
Fig. 9. Effect of PMA on promoter 3 activity and TPb mRNA expression levels. pGL3b:Prm1 or pGL3e:Prm1 (A), pGL3b:Prm2 or pGL3e:Prm2
(B) pGL3b:Prm3, or pGL3e:Prm3 (C) were transfected into HEL 92.1.7 cells. After 36 h, the cells were treated with PMA (100 nM; 12 h) with
vehicle/nonstimulated cells serving as a control. Thereafter, firefly and renilla luciferase activity was assayed and results are expressed as mean
relative luciferase activity, in arbritary units (RLU) ± SEM (n ¼ 6). (D) As a complementary approach, total RNAwas isolated fromHEL 92.1.7
cells treated with PMA (100 nM; 6 h), with vehicle only treated cells serving as a control. Following first strand cDNA synthesis, PCR amplifi-
cations were performed using the TP sense primer Kin16 in combination with the TPa specific antisense primer Kin75 or in combination with the
TPb-specific antisense primer, Kin21. As a positive control, amplification of GAPDH was performed using the primer pair Gf/Gr, as previously
described. (D) Agarose gel electrophoresis of RT-PCR products derived from first strand cDNA templates; lane 1, TPb, 269 bp product vs. primers
Kin16/21 derived from PMA treated cells; lane 2, TPa, 400 bp product vs. primers Kin16/Kin75 derived from PMA treated cells; lane 3, GAPDH,
983 bp product vs. primers Gf/Gr derived from PMA treated cells; lane 4, TPb, 269 bp product vs. primers Kin16/Kin21 derived from control cells;
lane 5, TPa, 400 bp product vs. primers Kin16/Kin75 derived from control cells; lane 6, GAPDH, 983 bp product vs. primers Gf/Gr derived from
control cells; lanes 7–9, negative control reactions performed in the absence of template first strand cDNA in the presence of the primer pairs Kin16/
Kin21, Kin16/Kin75 and Gf/Gr, respectively; lane M, pGEM DNA markers.
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identified 5¢ of E1 and E1b sequences, respectively, raised
the possibility for alternative promoter utilization within the
TP gene. Nu¨sing et al. [4] proposed that the major TP
mRNA transcripts contain E1, E2 and E3 sequences;
however, in aminority of cases, transcripts containing either
E1b, E2 and E3 or E1, E1b, E2 and E3 sequences were
identified [4]. Additionally, multiple transcription initiation
(TI) sites were identified for the human TP gene. Specific-
ally, employing primer extension analysis, a major TI site
was postulated at )289 within E1 in placental tissue [4]. In
contrast, multiple TI sites clustered around )140, )161 and
)173, within E1, were identified in placental tissue and
MEG-01 cells [4]. Additionally, in MEG-01 cells, TI sites
were also identified at )158 and )186, within E1b, and at
)69 and )79, within E2 [4]. Moreover, in the human
platelet-like K562 cell line and in human uterine tissue,
transcription initiation sites were identified at )123 within
E1 [6] and more recently, D’Angelo et al. [7] proposed that
the major TI site for the human TP actually occurs at )553,
upstream from the major TI, located at )289, previously
identified by Nu¨sing et al. [4]. Thus, in view of the apparent
discrepancies in the patterns of exon usage and the presence
of multiple TI sites, the initial aim of this study was to
characterize the major TPmRNA transcripts in HEL 92.1.7
cells and in trophoblast TM-1 cells and, thereafter, to
establish the molecular basis of the differential expression of
TPa and TPb.
We initially sought to characterize the major TP
transcripts, with respect to their possible divergent 5¢ UTR
sequences, and to map the TI sites therein. Using an
RT-PCR approach, it was established that while E1 and
E1b were found associated with TP transcripts in bothHEL
and TM-1 cells, their presence were mutually exclusive and
transcripts containing both E1 along with E1b, as postu-
lated by Nu¨sing et al. [4], were not identified. The exclusive
nature of E1 and E1b expression suggests that the putative
promoter P1 and P2 regions 5¢ of E1 and E1b, identified by
Nu¨sing et al. [4], may independently control the expression
of transcripts containing E1 and E1b, respectively. Of
course, our data cannot exclude the possibility that
initiation of transcription at one promoter (e.g. P1) may
serve to repress transcription at the other promoter (e.g. P2)
and vice versa, accounting for the exclusive nature of E1 and
E1b on the TP transcripts. Additionally, through 5¢RACE,
the major TI sites of TP mRNAs identified in both HEL
and TM-1 cells were found clustered between )115 and )92
within E1 and at )99 within E1b. The potential physiologic
significance of mRNAs that differ within the 5¢ UTR is
currently unknown but may be related to the tissue
dependent expression of the TPs.
Thereafter, to ascertain whether the TP isoforms may be
subject to alternative promoter utilization, we sought to
identify the 5¢ UTR sequences associated with the individ-
ual TPa and TPb mRNAs and to identify to the major TI
sites associated with those isoform specific transcripts.
Detailed RT-PCR analyses established that while both E1
or E1b sequences were associated with TPa transcripts,
these sequences were not found associatedwith TPbmRNA
transcripts. More specifically, it was established, in addition
to their defining differences within E3, that TPa and TPb
mRNA sequences also diverged at nucleotide )12 within
E2, suggesting that sequences surrounding the )12 region
may represent a novel splice acceptor site or, alternatively,
may actually correspond to the site of TI of the TPb
mRNA. Thereafter, through a number of independent
approaches employing 5¢ RACE, it was established that the
major TI of the TPb transcripts in both HEL and TM-1
cells mapped to the )12/)15 region. Moreover, no
additional TPb transcripts were identified with sequences
5¢ of )12/)15 suggesting that TPb mRNA expression may
be regulated by a novel promoter, P3, most likely located
immediately 5¢ of the )12 region, rather than the previously
identified P1 or P2.
Consistent with this, through genetic reporter assays, it
was established that a 1.39-kB DNA fragment correspond-
ing to sequences immediately flanking the )12 region could
direct the efficient basal transcription of luciferase in both
HEL 92.1.7 and HEK 293 cells. Functional transcriptional
activity was also confirmed for P1 and for P2 in both HEL
92.1.7 cells and in HEK 293 cells, consistent with previous
findings byNu¨sing et al. [4]. While P3 directed weaker basal
expression of luciferase relative to the P1, it was substan-
tially stronger than P2 in both HEL and HEK 293 cells. It
was noteworthy that we observed no significant cell-
dependent differences in the basal transcriptional activity
of P3 between either HEL orHEK 293 cells; however, while
the level of basal P1 transcriptional activity was significantly
lower in HEK 293 cells than in HEL cells (P ¼ 0.0035)
when expressed in the pGL3basic vector (pGL3b:Prm1),
this effect was negated when P3 was expressed in the
pGL3enhancer vector (pGL3e:Prm1). Confirmation of
functional transcriptional activity for P1 in the megakaryo-
cyte HEL 92.1.7 cell line is consistent with the studies of
D’Angelo et al. [6] in the megakaryocyte K562 cell line;
however, they failed to detect functional activity for P1 in
the fibroblast HEK 293 cells and failed to detect any
functional activity for P2 in either K562 or HEK 293 cells.
The most likely explanation for the apparent discrepancies
between our studies and those reported by D’Angelo et al.
[6] may be due to differences in the relative sensitivities of
the genetic reporter assays used; while we employed the
relatively sensitive, entirely quantitative, luciferase based
assay, those studies by D’Angelo et al. [6] were based on the
qualitative, relatively insensitive, chloramphenicol-based
assay system. Thus, we have identified a novel promoter
P3 immediately 5¢ of the )12 divergent region that, from
studies reported herein, most likely directs expression of
TPb.
Bioinformatic analyses of a 1.39-kb DNA fragment
encoding P3 revealed that, similar to that previously
established for P1 and P2 [4], it did not contain TATA or
CAAT boxes or a consensus initiator element found on
many common promoter elements [38,39]. It is widely
recognized that the TATA box and initiator elements have
an important role in directing transcription initiation from a
specific site [40] and, thus, it appears that TATA-less genes
contain multiple TI sites, consistent with that found for the
TP gene through earlier reports [4,6,7] and through studies
reported herein. Analysis of P3 sequences also identified the
presence of a number of signature transcription factor
binding sites including those for SREB and Oct-1 in
addition to a number of sites that may be regulated by
phorbol esters/protein kinase C signalling including sites for
SP-1 AP-1 and AP-4. In the current study, we established
that treatment of HEL cells with PMA led to significant
increases in P3-directed luciferase expression and also led to
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significant increases in TPb mRNA expression. Consistent
with that found by D’Angelo et al. [7], transcriptional
activity of P1, but not P2, was also up-regulated by PMA in
HEL cells. The importance of an SP-1 site in P1 has been
highlighted by D’Angelo et al. [7] who reported that PMA
up-regulation of P1 is mediated through an SP-1 site located
at a site corresponding to the )8273 to )8261 region
upstream of the +1 (ATG translational start site) within
the TP gene. While, in the current study, we have indeed
established that PMA up-regulates P3 transcriptional
activity, further detailed molecular investigations are
required to identify those specific transcription factor site(s)
that mediate(s) this effect; moreover, additional detailed
investigations are required to define the extent of P3
required for full promoter activity and to establish the
importance of other transcription factor binding sites in
directing P3 transcriptional activity.
Thus, through studies reported herein, it is evident that in
addition to their established differences in E3, due to the
presence (TPa) or absence (TPb) of intron 3b sequences, the
TPa and TPb transcripts also differ extensively in their 5¢
UTR sequences and are subject to differential regulation
through the transcriptional activity of P1/P2 and P3,
respectively. It is also evident that the 5¢ UTR of TPb
(12–15 bp) is appreciably shorter than that determined by
us and other investigators for TPa [4,6,7]. While it has been
reported that the optimum 5¢ UTR length for ribosomal
binding is 40–50 bp, sequences of 12–15 bp, such as that
found in the TPb mRNA, are sufficient for ribosomal
binding and to support efficient translation [41]. There are a
number of genetic precedences whereby protein/receptor
isoforms arise through differential splicing, being products
of the same gene, but may be under the transcriptional
control of separate or distinct promoters. Similar to the TP,
the human progesterone receptor (PR) exists as two
isoforms, referred to as PR-A and PR-B and, whilst they
arise through differential splicing, they are transcribed from
two distinct promoters within the single PR gene [42,43].
In vivo, the two PR isoforms are usually coexpressed in
normal tissues, yet the ratio of their expression varies
dramatically in different tissues, physiological states, and in
disease [43–46]. Similarly, alternative promoter usage by the
estrogen receptor (ER) a and ERb isoforms has been shown
to be responsible for the disparate distribution of both
receptors [47,48]. In the case of the murine calcitonin
receptor, three individual promoters direct the expression of
at least seven murine calcitonin receptor isoforms that
exhibit differences in their 5¢ UTR sequences and in their
profiles of tissue expression [49].
In keeping with these diverse examples, there is a growing
awareness that transcription and splicing might not be
independent events as previously held, but on the contrary,
may be highly co-ordinated processes both at the functional
and structural levels [50–52]. It is thought that distinct
promoters within a given gene may direct the transcription
and pattern of splicing events, and indeed 5¢ capping and
polyadenylation, of distinct transcripts leading to the
generation of distinct promoter-driven, differentially spliced
mRNA end products. Alternative mRNA splicing is a
common feature within a large number of the diverse
superfamily of GPCRs, not least among the prostanoid
receptor subfamily of GPCRs [53]. The EP3 subtype of the
PGE2 receptors is one of the most heavily spliced among all
of the GPCRs, with eight splice variants or isoforms
identified in human that differ exclusively in their C-tail
sequences [53]. Similarly, alternative spliced isoforms of the
humanEP1 and ovine FP receptors have also been reported,
where similar to the TPs, isoform differences are confined to
their respective C-tail domains [54,55]. The discovery that
the expression of human TPa and TPb isoforms is
controlled by differential promoter utilization, in additional
to differential splicing, may have major implications for
how the expression of other prostanoid receptor isoforms
are regulated. Thus, further investigation of those genes
encoding prostanoid receptor isoforms and indeed those
genes encoding GPCRs that undergo differential splicing
may uncover similar patterns of transcriptional regulation
to that identified in the current study for the human TP.
In summary, we have shown that the 5¢UTRs of TPa and
TPb diverge at )12 within E2 and that transcription of TPb
initiates at )12/)15 and is controlled by a novel promoter,
P3, located 5¢ of E2. Further characterization of the
functional elements within P3 will provide a more complete
understanding of the factors regulating TPb expression and,
indeed, are likely to shed further insight on the specific role
of TPb and, more specifically, on the physiologic require-
ment for two distinct TP receptors, namely TPa and TPb, in
human tissues.
A C K N O W L E D G E M E N T S
This research was supported by grants to BTK from The Health
Research Board of Ireland, The Wellcome Trust and Enterprise
Ireland.
R E F E R E N C E S
1. Narumiya, S., Sugimoto, Y. & Ushikubi, F. (1999) Prostanoid
Receptors: Structures, properties, and functions. Physiol. Rev. 79,
1193–1226.
2. Hirata,M., Hayashi, Y., Ushikubi, F., Yokota, R., Kageyama, S.,
Nakanishi, S. & Narumiya, S. (1991) Cloning and expression of
the cDNA for a human thromboxane A2 receptor. Nature. 349,
617–620.
3. Raychowdhury, M.K., Yukawa, M., Collins, L.J., McGrail, S.H.,
Kent, K.C. & Ware, J.A. (1994) Alternative splicing produces a
divergent cytoplasmic tail in the human endothelial thromboxane
A2 receptor. J. Biol. Chem. 269, 19256–19261.
4. Nu¨sing, R.M., Hirata, M., Kakizuka, A., Eki, T., Ozawa, K. &
Narumiya, S.J. (1993) Characterization and chromosomal map-
ping of the human thromboxane A2 receptor gene. J. Biol. Chem.
268, 25253–25259.
5. Kinsella, B.T., O’Mahony, D.J. & FitzGerald, G.A. (1994a)
Phosphorylation and regulated expression of the human throm-
boxane A2 receptor. J. Biol. Chem. 269, 29914–29919.
6. D’Angelo, D.D., Davis, M.G., Houser, W.A., Eubank, J.J.,
Ritchie, M.E. & Dorn, G.W. 2nd. (1995) Characterization of 5¢
end of human thromboxane receptor gene. Organizational ana-
lysis and mapping of protein kinase C – responsive elements
regulating expression in platelets. Circ. Res. 77, 466–474.
7. D’Angelo, D.D., Oliver, B.G., Davis, M.G., McCluskey, T.S. &
Dorn, G.W. (1996) Novel role for Sp1 in phorbol ester enhance-
ment of human platelet thromboxane receptor gene expression.
J. Biol. Chem. 271, 19696–19704.
8. Hirata, T., Ushikubi, F., Kakizuka, A., Okuma, M. & Narumiya,
S. (1996) Two thromboxane A2 receptor isoforms in human pla-
telets – Opposite coupling to adenylyl cyclase with different sen-
sitivity to Arg60 to Leu mutation. J. Clin. Invest. 97, 949–956.
 FEBS 2002 Analysis of the TPa and TPb mRNAs (Eur. J. Biochem. 269) 4071
9. Vezza, R., Habib, A. & FitzGerald, G.A. (1999) Differential sig-
naling by the thromboxane receptor isoforms via the novel GTP-
binding protein, Gh. J. Biol. Chem. 274, 12774–12779.
10. Walsh, M.-T., Foley, J.F. & Kinsella, B.T. (2000) Investigation of
the role of the carboxyl terminal tails of the a and b isoforms of the
human thromboxane A2 receptor (TP) in mediating receptor:
effector coupling. Biochem. Biophys. Acta 1496, 164–182.
11. Kinsella, B.T. (2001) Thromboxane A2 signalling in humans: a
tail of two receptors. Biochem. Soc. Transactions 29, 641–654.
12. Walsh, M.-T., Foley, J.F. & Kinsella, B.T. (2000) The a, but not
the b, isoform of the human thromboxane A2 receptor (TP) is a
target for prostacyclin mediated desensitization. J. Biol. Chem.
275, 20412–20423.
13. Foley, J.F., Kelley, L.P. & Kinsella, B.T. (2001) Prostaglandin
D(2) receptor-mediated desensitization of the alpha isoform of the
human thromboxane A(2) receptor.Biochem. Pharmacol. 62, 229–
239.
14. Walsh, M.T. & Kinsella, B.T. (2000) Regulation of the human
prostanoid TPalpha and TPbeta receptor isoforms mediated
through activation of the EP(1) and IP receptors.Br. J. Pharmacol.
131, 601–609.
15. Parent, J.-L., Labrecrue, P., Orsini, M.J. & Benovic, J.L. (1999)
Internalization of the TXA2 receptor a and b isoforms. J. Biol.
Chem. 274, 8941–8948.
16. Parent, J.L., Labrecque, P., Driss Rochdi, M. & Benovic, J.L.
(2001) Role of the differentially spliced carboxyl terminus in
thromboxane A2 receptor trafficking: identification of a distinct
motif for tonic internalization. J. Biol. Chem. 276, 7079–7085.
17. Miggin, S.M. & Kinsella, B.T. (1998) Expression and tissue dis-
tribution of the mRNAs encoding the human thromboxane A2
receptor (TP) alpha and beta isoforms. Biochim. Biophys. Acta.
1425, 543–559.
18. Habib, A., FitzGerald, G.A. & Maclouf, J. (1999) Phosphoryla-
tion of the thromboxane receptor, the predominant isoform
expressed in human platelets. J. Biol. Chem. 274, 2645–2651.
19. Miggin, S.M. & Kinsella, B.T. (2001) Thromboxane A2 receptor
mediated activation of the mitogen activated protein kinase cas-
cades in human uterine smooth muscle cells. Biochem. Biophys.
Acta 1539, 147–162.
20. Papayannopoulou, T., Nakamoto, B., Yokochi, T., Chait, A. &
Kannagi, R. (1983) Human erythroleukemia cell line (HEL)
undergoes a drastic macrophage-like shift with TPA. Blood. 62,
832–845.
21. Sambrook, J., Fritsch, E.F. & Maniatis, T. (1989) Molecular
Cloning: A Laboratory Manual, 2nd edn. Cold Spring. Harbor
Laboratory Press, Cold Spring Harbor, NY.
22. Kinsella, B.T., O’Mahony, D.J., Lawson, J.A., Pratico, D. &
FitzGerald, G.A. (1994b) Cellular activation of thromboxane
receptors. Ann. NY Acad. Sciences 714, 270–278.
23. Quandt, K., Frech, K., Karas, H., Wingender, E. & Werner, T.
(1995) MatInd and MatInspector: new fast and versatile tools for
detection of consensus matches in nucleotide sequence data.
Nucleic Acids Res. 23, 4878–4884.
24. Armstrong, R.A. (1996) Platelet prostanoid receptors. Pharmacol.
Ther. 72, 171–191.
25. Dorn, G.W.I.I. & Becker, M.W. (1992) Thromboxane A2 stimu-
lated signal transduction in vascular smoothmuscle. J. Pharmacol.
Exp. Ther. 265, 447–456.
26. Hanasaki, K., Nakano, K. & Arita, H. (1988) Receptor-mediated
mitogenic effect of thromboxane A2 in vascular smooth muscle
cells. Biochem. Pharmacol. 40, 2535–2542.
27. Dorn II, G.W., Becker, M.W. & Davis, M.G. (1992) Dissociation
of the contractile and hypertrophic effects of vasoconstrictor
prostanoids in vascular smooth muscle. J. Biol. Chem. 267, 24897–
24905.
28. Ali, S., Davis, M.G., Becker, M.W. & Dorn, 11, G.W. (1993)
Thromboxane A2 stimulates vascular smooth muscle hypertrophy
by up-regulating the synthesis and release of endogenous basic
fibroblast growth factor. J. Biol. Chem. 268, 17397–17403.
29. Lianos, E.A. & Bresnahan, B.A. (1999) Effect of thromboxane A2
inhibition and antagonism on prostaglandin and leukotriene
synthesis in glomerular immune injury. J. Laboratory Clin. Med.
134, 478–482.
30. Ushikubi, F., Aiba, Y., Nakamura, K., Namba, T., Hirata, M.,
Mazda, O., Katsura, Y. & Narumiya, S. (1993) Thromboxane A2
receptor is highly expressed in mouse immature thymocytes and
mediates DNA fragmentation and apoptosis. J. Exp. Med. 178,
1825–1830.
31. Oates, J.A., FitzGerald, G.A., Branch, R.A., Jackson, E.K.,
Knapp, H.R. & Roberts, L.J. 2nd (1988) Clinical implications of
prostaglandin and thromboxane A2 formation. N. Engl. J. Med.
319, 689–698.
32. Fitzgerald, D.J., Rocki, W., Murray, R., Mayo, G. & FitzGerald,
G.A. (1990) Thromboxane A2 synthesis in pregnancy-induced
hypertension. Lancet 335, 751–754.
33. Dorn, G.W., 2nd, Liel, N., Trask, J.L., Mais, D.E., Assey,M.E. &
Halushka, P.V. (1990) Increased platelet thromboxane A2/pros-
taglandin H2 receptors in patients with acute myocardial infarc-
tion. Circulation 81, 212–218.
34. Thomas, D.W., Mannon, R.B., Mannon, P.J., Latour, A., Oliver,
J.A., Hoffman, M., Smithies, O., Koller, B.H. & Coffman, T.M.
(1998) Coagulation defects and altered hemodynamic responses in
mice lacking receptors for thromboxane A2. J. Clin. Invest. 102,
1994–2001.
35. Kinsella, B.T., O’Mahony, D.J. & Fitzgerald, G.A. (1997) The
human thromboxane A2 receptor alpha isoform (TPalpha) func-
tionally couples to the G proteins Gq and G11 in vivo and is
activated by the isoprostane 8-epi prostaglandin F2 alpha.
J. Pharmacol. Exp. Ther. 281, 957–964.
36. Janssen, L.J. (2001) Isoprostanes: an overview and putative roles
in pulmonary pathophysiology. Am. J. Physiol. Lung Mol. Phys-
iol. 280, L1067– L1082.
37. Miggin, S.M. & Kinsella, B.T. (2002) Regulation of the extra-
cellular signal regulated protein kinase cascades by the a and b
isoforms of the human thromboxane A2 receptor. Mol. Pharma-
col. 61, 817–831.
38. Hu, S.L. & Manley, J.L. (1981) DNA sequence required for
initiation of transcription in vitro from the major late promoter of
adenovirus 2. Proc. Natl Acad. Sci. USA 78, 820–824.
39. Tan, S. & Richmond, T.J. (1998) Eukaryotic transcription factors.
Curr. Opin. Struct. Biol. 8, 41–48.
40. Smale, S.T. (1997) Transcription initiation from TATA-less pro-
moters within eukaryotic protein-coding genes. Biochim. Biophys.
Acta 1351, 73–88.
41. Javahery, R., Khachi, A., Lo, K., Zenzie-Gregory, B. &
Smale, S.T. (1994) DNA sequence requirements for trans-
criptional initiator activity in mammalian cells. Mol. Cell 14,
116–127.
42. Kastner, P., Krust, A., Turcotte, B., Stropp, U., Tora, L.,
Gronemeyer, H. & Chambon, P. (1990) Two distinct estrogen-
regulated promoters generate transcripts encoding the two func-
tionally different human progesterone receptor forms A and B.
EMBO J. 9, 1603–1014.
43. Richer, J.K., Jacobsen, B.M., Manning, N.G., Abel, M.G., Wolf,
D.M. & Horwitz, K.B. (2002) Differential gene regulation by the
two progesterone receptor isoforms in human breast cancer cells.
J. Biol. Chem. 277, 5209–5218.
44. Boyd-Leinen, P.A., Fournier, D. & Spelsberg, T.C. (1982) Non-
functioning progesterone receptors in the developed oviducts from
estrogen-withdrawn immature chicks and in aged nonlaying hens.
Endocrinology 111, 30–36.
45. Spelsberg, T.C. & Halberg, F. (1980) Circannual rhythms in
steroid receptor concentration and nuclear binding in the chick
oviduct. Endocrinology 107, 1234–1244.
4072 A. T. Coyle et al. (Eur. J. Biochem. 269)  FEBS 2002
46. Kato, J., Hirata, S., Nozawa, A.&Mouri, N. (1993) The ontogeny
of gene expression of progestin receptors in the female rat brain.
J. Steroid Biochem. Mol. Biol. 47, 173–182.
47. Donaghue, C., Westley, B.R. & May, F.E. (1999) Selective pro-
moter usage of the human estrogen receptor-alpha gene and its
regulation by estrogen.Mol. Endocrinol. 13, 1934–1950.
48. Li, L.C., Yeh, C.C., Nojima, D. & Dahiya, R. (2000) Cloning and
characterization of human estrogen receptor beta promoter.
Biochem. Biophys. Res. Commun. 275, 682–689.
49. Anusaksathien, O., Laplace, C., Li, X., Ren, Y., Peng, L., Gold-
ring, S.R. & Galson, D.L. (2001) Tissue-specific and ubiquitous
promoters direct the expression of alternatively spliced transcripts
from the calcitonin receptor gene. J. Biol. Chem. 276, 22663–
22674.
50. Xing, Y., Johnson, C.V., Dobner, P.R. & Lawrence, J.B. (1993)
Higher level organization of individual gene transcription and
RNA splicing. Science 259, 1326–1330.
51. Cramer, P., Pesce, C.G., Baralle, F.E. & Kornblihtt, A.R.
(1997) Functional association between promoter structure and
transcript alternative splicing. Proc. Natl Acad. Sci. USA 94,
11456–11460.
52. Caceres, J.F. & Kornblihtt, A.R. (2002) Alternative splicing:
multiple control mechanisms and involvement in human diseases.
Trends Genet. 18, 186–193.
53. Kilpatrick, G.J., Dautzenberg, F.M.,Martin, G.R. & Eglen, R.M.
(1999) 7TM receptors: the splicing on the cake. Trends Pharmacol.
Sci. 20, 294–301.
54. Okuda-Ashitaka, E., Sakamoto, K., Ezashi, T., Miwa, K., Ito, S.
& Hayaishi, O. (1996) Suppression of prostaglandin E receptor
signaling by the variant form of EP1 subtype. J. Biol. Chem. 271,
31255–31261.
55. Anthony, T.L., Pierce, K.L., Stamer, W.D. & Regan, J.W. (1998)
Prostaglandin F2 alpha receptors in the human trabecular mesh-
work. Invest. Ophthalmol. Vis. Sci. 39, 315–321.
 FEBS 2002 Analysis of the TPa and TPb mRNAs (Eur. J. Biochem. 269) 4073
